Page
What Is Xgeva?Xgeva® (denosumab) is a monoclonal antibody that prevents bone complications in myeloma patients. Our bodies have a delicate balance between cells that build bone (osteoblasts) and cells that break down bone (osteoclasts). For myeloma patients, signals sent by cancerous myeloma cells…
Videos
BloodFlow: A New Next Generation Flow (NGF) Blood Test
Myeloma expert Dr. Brian G.M. Durie discusses the new NGF blood test called BloodFlow and how this blood test can be used to detect minimal residual disease (MRD) at a sensitive level.
The BOTTOM LINE: This…
Page
Corporate and foundation support is critical to advance the IMF’s mission of improving the quality of patients’ lives while working toward prevention and a cure. Partnering with the IMF is a wise investment in the future and provides value for your company. The IMF can guide your giving strategy so…
Event
Many of you know of my journey with MM from my Diagnosis in 2008. In 2008 and 09, I was in a wheelchair and then a walker. Starting in 2010 I was using Nordic Walking sticks to get around and finally got back on the bicycle in late summer. In 2011 I took my first bicycle trip to…
Videos
Mass Spectrometry and Next-Generation Flow
Myeloma expert Dr. Brian G.M. Durie discusses how mass spectrometry and next-generation flow can be used to predict the length of remission.
The BOTTOM LINE: Mass spectrometry and next-generation flow can be used to…
Videos
Myeloma Risk Factors By Race and Ethnicity
Dr. Tondre Buck presents an abstract on real-world multiple myeloma risk factors and outcomes by race/ethnicity in the United States.
Abstract title:
Real-World Multiple Myeloma Risk Factors and Outcomes By Race/Ethnicity in the United States…
Page
What Is Minimal Residual Disease Testing?MRD testing for myeloma refers to the detection of very small numbers of myeloma cells that may remain in the body after treatment. These cells are often so few that they don't cause symptoms and are undetectable by standard…
Videos
Bispecifics Part 4: The Science of Bispecific Antibodies
What are current bispecific antibodies and how do they work?
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael explains how both monoclonal antibodies and bispecific antibodies are designed to specifically attach to a precise…
Videos
Bispecifics Part 3: The Pros and Cons of BispecificsWhat are the pros and cons of bispecific therapies?In this video, IMF Medical Advisor Dr. Joseph Mikhael discusses the main benefits of bispecific antibody therapies, such as the ability to administer these drugs off the shelf, their mechanisms of…
Videos
Bispecifics Part 2: Monoclonal and Bispecific AntibodiesWhat are the differences among monoclonal antibodies, CAR T-cell therapies, and bispecific antibodies?In this video, IMF Medical Advisor Dr. Joseph Mikhael defines and explains the differences between monoclonal antibodies and bispecific…
Videos
Bispecific Antibodies Part 1: Immune System and Immunotherapy BasicsWhat is immunotherapy?In this video, IMF Medical Advisor Dr. Joseph Mikhael explains the basics of the immune system, including Natural Kill (NK) cells, and T cells. He discusses antibody immunity, or the “complicated…
Videos
Talquetamab in Relapsed Myeloma Patients
Dr. Ajai Chari presents an abstract on Talquetamab in patients with relapsed refractory multiple myeloma.
Abstract title:
Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/…
Videos
Idecabtagene Vicleucel in Post-Stem Cell Transplant Myeloma Patients
Dr. Saad Usmani presents an abstract on the efficacy and safety of Idecabtagene Vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. …
Videos
When Should MGUS Patients Undergo Bone Marrow Biopsy?
Myeloma expert Dr. Brian G.M. Durie discusses how the IMF’s iStopMM study results presented at the 2022 American Society of Hematology (ASH) meeting may help predict when a bone marrow biopsy is needed. …
Videos
Dr. Gary Schiller, UCLA David Geffen School of Medicine, presents the results of once weekly Selinexor, Carfilzomib and Dexamethasone in triple class refractory multiple myeloma.
Background:
Selinexor, an oral exportin-1 inhibitor, is approved for the treatment of relapsed/refractory multiple…
News Article
GMAN Meeting at the American Society of Hematology 2022
On Thursday, December 15th, 2022, more than 30 members of the Global Myeloma Action Network (GMAN) came together for a virtual meeting to review the key outputs of the American Society of Hematology (ASH) conference held in New…
Page
A Message From IMF President and CEO, Yelak Biru
Watch IMF President and CEO—as well as 27-year multiple myeloma survivor—Yelak Biru reflect on the impact of the IMF in 2022 and share his vision for the future.
Videos
Chronic Kidney Disease in MGUS Patients
Dr. Thorir Einarsson Long presents an abstract to compare the prevalence of chronic kidney disease in individuals with and without monoclonal gammopathy of undetermined significance in a large, prospective, screened, population-based…
Videos
Circulating Tumor Cells in iStopMM Study
Dr. Sigrún Thorsteinsdóttir presents a study on circulating tumor plasma cells in peripheral blood and its correlation to progression from smoldering multiple myeloma to multiple myeloma.
Abstract title:
Circulating…
Videos
Dr. Noemi Puig, University of Salamanca, discusses an abstract on the clinical impact of Next Generation Flow in bone marrow vs QiP-Mass Spectrometry in peripheral blood to assess Minimal Residual Disease in newly diagnosed multiple myeloma patients.
Background:
GEM2014MAIN is a phase 3,…
Videos
Measuring MRD in Myeloma Patients with Bloodflow Method
Dr. Laura Notarfranchi presents the results of ultra-sensitive assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of multiple myeloma patients using Bloodflow
Abstract title:
Ultra-Sensitive Assessment of…
Videos
No Link Found Between Autoimmune Disease and MGUS
Dr. Ingigerdur Sverrisdottir presents an abstract on the relationship between monoclonal gammopathy of undetermined significance (MGUS) and autoimmune diseases.
Abstract title:
Autoimmune Diseases Are Not Associated with Monoclonal…
Videos
iStopMM Results of Hypercalcemia in Patients with MGUS
Dr. Ástrún Helga Jónsdóttir presents the results of an iStopMM study regarding hypercalcemia in individuals with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Abstract title:…
Videos
Racial and Ethnic Differences Among CAR T-cell Therapy for Multiple Myeloma Patients
Dr. Lauren Peres presents an abstract on the racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy.
Abstract title:
Racial and Ethnic…
Videos
GEM-CESAR Curative Strategy for High-Risk Smoldering Multiple Myeloma
Dr. Maria Victoria Mateos presents curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM), a post-hoc analysis of sustained undetectable measurable residual disease (MRD).
Abstract title:
Curative…
Videos
In this iStopMM study Jon Þórir Oskarsson presents the results of determining hemodilution in diagnostic bone marrow samples in multiple myeloma and its precursors by Next-Generation Flow Cytometry (NGF).
Background:
A major limitation for quantification of bone marrow (BM) plasma cells (PC)…
Videos
The Impact of Hispanic Ethnicity on Multiple Myeloma
Dr. Kara Cicero presents a study on the impact of Hispanic ethnicity on disease characteristics in multiple myeloma
Abstract title:
The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma
Purpose of the…
Videos
ASH 2022: Making Sense of Treatment
In the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discuss the latest myeloma news from the 64th American Society of Hematology Annual Meeting in December 2022
Moderated by IMF Chairman of the Board Dr. Brian G.M.…
Videos
SARS-CoV-2 Vaccination's Impact on the Progression of MGUS to MM
Dr. Robert Palmason discusses the results of a study investigating if SARS-CoV-2 vaccination impacts the risk of progression from MGUS to multiple myeloma
Abstract Title:
105 Sars-…
Videos
The iStopMM Study on Transient M-Proteins and the Use of Mass Spectometry for the Evaluation of Monoclonal Proteins
Dr. Robert Palmason discusses the epidemiology of individuals with transient M-proteins in the prospective screening manner based on the Iceland Screens, Treats, or…
Videos
Updated Results of the IMF ASCENT Trial Were Presented at the 2022 ASH Meeting
Myeloma expert Dr. Brian G.M. Durie discusses the International Myeloma Foundation’s Black Swan Research Initiative-funded ASCENT trial—one of the myeloma “cure” trials funded…
Videos
MRD2STOP: Impact of Multimodal MRD Negativity on Discontinuation of Maintenance Treatment Presented at ASH 2022
Dr. Ben Derman discusses the MRD2STOP study on the impact of multimodal MRD negativity allowing for the discontinuation of myeloma maintenance treatment
Dr. Ben Derman of the…
Videos
Are Bisphosphonates Still the Standard of Care Recommendation?
Myeloma expert Dr. Brian G.M. Durie discusses how myeloma patients can manage bone disease and the reason why treatment is recommended even to those without bone disease symptoms.
The BOTTOM LINE: …
Videos
Are Bisphosphonates Still the Standard of Care Recommendation?
Myeloma expert Dr. Brian G.M. Durie discusses how myeloma patients can manage bone disease and the reason why treatment is recommended even to those without bone disease symptoms.
The BOTTOM LINE: …
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the…
News Article
STUDIO CITY, Calif., Dec. 01, 2022 -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE Grant…
IMF Person
Narmeen Shammami is a Research Project Manager with experience overseeing research projects from initiation to completion. She coordinates contracts, budgets, regulatory materials, site activities, and communication with researchers and partners across institutions. She is also involved in…
Audio
An Interview with Support Group Leader Carl Burgman
A Myeloma Patient’s Journey from Receiving a Myeloma Diagnosis to Leading a Support Group
In this episode of the “A Day in the Life” podcast, myeloma patient and support group leader Carl Burgman discusses his myeloma journey with the IMF…
News Article
Blenrep Withdrawal: What Myeloma Patients Need to Know
On November 22, 2022, GSK announced it has initiated the process for withdrawal of the U.S. marketing authorization for…
News Article
GSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf) following the request of the US Food and Drug Administration (FDA). This request was based on the previously announced outcome of the DREAMM-…
IMF Person
Based in St. Petersburg, Florida, Daria Tabota joins the IMF with a wealth of digital marketing, social media, and public relations experience. As the IMF’s MarCom Associate, she is responsible for helping manage the organization’s digital assets and works with the MarCom team on social media and…
Videos
Speakers
Jens Hillengass, MD, PhD (Roswell Park Comprehensive Cancer Center, Buffalo, NY)
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN (Cleveland Clinic – Taussig Cancer Institute, IMF Nurse Leadership Board)
What to Expect
By attending this webinar, our…
News Article
The Creatives Against Cancer fundraising event was held on Saturday, October 8 at Brightside Studios in Phoenix, AZ. Organized by Brightside Studios owners Brad and Vanessa Kuenn, along with Brad’s sister Hillary Kuenn, the event was able to raise $6,161, with…
News Article
Paul Gater—an 8.5-year myeloma patient and a member of the San Francisco Bay Area Support Group—was nominated by the International Myeloma Foundation (IMF) in May 2021 and is currently serving as a consumer reviewer for the Congressionally Directed Medical Research Programs (CDMRP). Paul…
News Article
One of the longest running 5K run/walk fundraisers in support of the International Myeloma Foundation (IMF), the Annual Miracles for Myeloma 5K Hybrid Run/Walk, proudly celebrated its 10th anniversary this year and rightly so.
For the past nine years, the annual 5K event has raised…
News Article
STUDIO CITY, CA, OCTOBER 27, 2022—The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her husband, Jimmy Scipione.
The Scip & Savor for a Cure Fundraiser was held on Saturday,…
News Article
On Tuesday, October 25, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Tecvayli™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously…